CARB-X Grants Debiopharm an Additional $12.3 Million to Advance Development of Novel Antibiotic Against Gonorrhea
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, is honored to share that it was awarded further funding from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership that accelerates antibacterial research and development to protect lives from bacterial infections. This grant will support the continued clinical development of Debio 1453, a first-in-class antibiotic with a novel mechanism of action to treat Neisseria gonorrhoeae infections.
The initial grant of $7.9 million USD has been instrumental in progressing Debio 1453 through preclinical research. The newly awarded grant is projected to amount to $12.3 million USD, broken down into 2 parts. Part 1 will contribute to further advancing Debio 1453 to Phase I first-in-human (FIH) evaluation. Part 2 of the grant will be considered by CARB-X based upon the achievement of predetermined milestones. Altogether, CARB-X’s award to Debiopharm is projected to reach more than $20 million USD in total to secure the transition of Debio 1453 from a preclinical to a clinical stage asset, including the timely commencement of Phase 2 evaluation, in line with their commitment to addressing the rising threat of drug-resistant bacteria.
“We are very pleased to receive this additional commitment from CARB-X for Debio 1453. This further confirms our strong pre-clinical proof-of-concept obtained for the treatment of gonorrhea,” explained Morgane Vanbiervliet, Director, Global Development and Licensing. “CARB-X’s commitment closely aligns with our own vision to establish a new standard of care for the treatment of N. gonorrhoeae infections, by developing an antibiotic with an entirely new mechanism of action and offering a crucial treatment alternative against multi-drug-resistant infections.”
“Debio 1453 represents an approach to resistance targeting that CARB-X is proud to support. With its novel mechanism of action and novelty in chemistry, this first-in-class antibiotic has the potential to offer a durable solution to treating gonorrhea, for which all but one antibiotic has been rendered ineffective,” said Erin Duffy, PhD, R&D Chief of CARB-X. “We are excited to continue supporting Debiopharm as the project advances into human clinical studies, marking a vital step toward delivering new treatment options for doctors and patients around the world.”
Debio 1453 is a potent inhibitor of the essential fatty acid synthesis enzyme FabI found in N. gonorrhoeae and a few other bacterial species. It was shown to rapidly trigger bactericidal activity in vitro and in vivo against N. gonorrhoeae, offering potential for treating difficult N. gonorrhoeae infections.
Due to its growing resistance to existing antibiotics, N. gonorrhoeae has become a major public health concern. New treatments are urgently needed to prevent serious complications like pelvic inflammatory disease, infertility, and increased risk of other infections. Gonorrhea can also be transmitted from a pregnant mother to her baby, potentially causing sepsis and neonatal conjunctivitis, which can, in turn, lead to blindness if untreated. In 2023, the United States reported a total of 601,319 cases of gonorrhea, making it the second most common nationally notifiable STI in the country.1 In the same year, 96,969 confirmed cases of gonorrhea were reported in 28 EU/EEA countries, with a notification rate of 25.0 cases per 100,000 individuals. This marks a 31% increase from 2022.2 The development of new antibiotics effective against N. gonorrhoeae is ranked high priority by the WHO and drug-resistant N. gonorrhoeae is considered an urgent threat by the US CDC.
Research reported in this press release is supported by CARB-X. CARB-X’s funding for this project is provided in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number: 75A50122C00028, and by awards from Wellcome (WT224842), Germany’s Federal Ministry of Education and Research (BMBF), the UK Department of Health and Social Care as part of the Global Antimicrobial Resistance Innovation Fund (GAMRIF) and the Novo Nordisk Foundation. The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders.
About CARB-X
CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global non-profit partnership dedicated to supporting early-stage antibacterial research and development to address the rising threat of drug-resistant bacteria. CARB-X supports innovative therapeutics, preventatives and rapid diagnostics. CARB-X is led by Boston University and funded by a consortium of governments and foundations. CARB-X funds only projects that target the most serious, resistant bacteria identified on global priority lists, syndromes with the greatest global morbidity and mortality, and performance characteristics necessary for patients. https://carb-x.org/ | X (formerly Twitter) @CARB_X
Debiopharm’s commitment to patients
Debiopharm aims to develop innovative therapies that target high unmet medical needs primarily in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then hand stewardship to large pharmaceutical commercialization partners to maximize patient access globally.
Visit us: www.debiopharm.com/drug-development/
Follow us: https://www.linkedin.com/company/debiopharminternational/
References
- U.S. Centers for Disease Control and Prevention (CDC). National Overview of STIs in 2023 I STIs Statistics I CDC (https://www.cdc.gov/sti-statistics/annual/summary.html)
- European Centre for Disease Prevention and Control. An agency of the European Union. Gonorrhoea – Annual Epidemiological Report for 2023 (https://www.ecdc.europa.eu/en/publications-data/gonorrhoea-annual-epidemiological-report-2023)
View source version on businesswire.com: https://www.businesswire.com/news/home/20250528860354/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer Stratence Partners30.5.2025 16:07:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform med en samarbejdsaftale med Stratence Partners, der er et konsulentfirma med base i Storbritannien, som hjælper globale virksomheder med at øge markedsandele og forbedre rentabiliteten gennem deres ekspertise inden for prisfastsættelse, strategisk optimering, kommerciel effektivitet og digital transformation. Stratence Partners har en resultatorienteret tilgang og er forpligtet på bæredygtig forandring, hvorved de hjælper deres kunder gennem en unik kombination af konsulentbistand, midlertidige ledelsesindsater og oplæringskurser samt deres egne metoder og løsninger inden for datastyring, datavidenskab (AI), værktøjer og systemer. "Samarbejdet med Andersen Consulting er et spændende skridt for vores firma," sagde Fernando Ventureira, administrerende direktør for Stratence Partners. "I vores arbejde med hos ledere over hele verden har vi erfaret, at deres behov rækker ud over strategisk prisfastsættelse og driftsoptimering. Vores kunder værdsætte
You Up? Grindr’s “Right Now” Goes Global30.5.2025 15:00:00 CEST | Press release
More places, more people – Grindr’s real-time hookup feature makes connecting faster than ever Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 14:00:00 CEST | Press release
Only approximately 2 out of 10 people in the US and 3 out of 10 people in Europe with certain rare, advanced blood cancers receive access to CAR T-cell therapy1,2,3New roadmap report aims to inspire collective action of stakeholder groups and invites additional CAR T-cell therapy leaders to join the coalition Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative fin
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 11:17:00 CEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur® Peripheral Retrievable Stent System30.5.2025 06:08:00 CEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom